%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
133 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-27T11:37:13Z
2024-03-28T22:49:19-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:49:19-07:00
application/pdf
Heather
2003-186.jan
uuid:7f0cb449-1dd2-11b2-0a00-8109275dc400
uuid:7f0cb44b-1dd2-11b2-0a00-810000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
159 0 obj
[163 0 R]
endobj
160 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
-0.02769 Tw 8 0 0 8 54 703.1616 Tm
[(W)79.9 (e thank the staf)17.7 (f of the Metabolic Research Unit at the Jean Mayer USDA)]TJ
0.134 Tw 0 -1.25 TD
[(Human Nutrition Research Center on )54.9 (Aging at )17.8 (T)35 (ufts University and our)]TJ
0.0657 Tw T*
[(volunteers for dedicating the time and ener)17.7 (gy required to make this study)]TJ
0 Tw T*
(possible.)Tj
/T1_0 1 Tf
10 0 0 10 54 649.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 639.1616 Tm
[(1.)-875.1 (Munro R, Capell H. Prevalence of low body mass in rheumatoid)]TJ
1.675 -1.25 Td
[(arthritis: association with the acute phase response. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1997;56:326-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (W)79.9 (esthovens R, Nijs J, )17.7 (T)69.9 (aelman )17.7 (V)128.9 (, Dequeker J. Body composition in)]TJ
1.675 -1.25 Td
(rheumatoid arthritis. Br J Rheumatol 1997;36:444-8.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Roubenof)17.7 (f R, Roubenof)17.7 (f R, )17.7 (W)79.9 (ard L, Holland S, Hellmann D.)]TJ
1.675 -1.25 Td
(Rheumatoid cachexia: depletion of lean body mass in rheumatoid)Tj
T*
[(arthritis. Possible association with tumor necrosis factor)54.8 (. )]TJ
T*
(J Rheumatol 1992;19:1505-10.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Moore FD. Ener)17.7 (gy and the maintenance of body cell mass. )]TJ
1.675 -1.25 Td
(J Parenter Enteral Nutr 1980;4:228-60.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Cahill GF)79.7 (. Starvation in man. N Engl J Med 1972;282:668-75.)]TJ
T*
[(6.)-875.1 (W)39.8 (inick M, editor)54.8 (. Hunger disease. New )36.8 (Y)99.8 (ork: John )17.7 (W)39.8 (iley & Sons;)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1979:261.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Kotler DP)110.7 (, )17.7 (T)35 (ierney )54.8 (AR, Pierson RN. Magnitude of body cell mass)]TJ
1.675 -1.25 Td
[(depletion and the timing of death from wasting in )54.8 (AIDS. )54.8 (Am J Clin)]TJ
T*
(Nutr 1989;50:444-7.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (DeW)59.7 (ys )17.7 (WD, Begg C, Lavin PT)73.9 (, et al. Prognostic ef)17.7 (fect of weight)]TJ
1.675 -1.25 Td
[(loss prior to chemotherapy in cancer patients. )54.8 (Am J Med)]TJ
0 Tc 0 Tw T*
(1980;69:491-7.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.2375 Td
[(9.)-875.1 (Roubenof)17.7 (f R, Roubenof)17.7 (f R, Cannon J, et al. Rheumatoid cachexia:)]TJ
1.675 -1.2375 Td
(cytokine-driven hypermetabolism accompanying reduced body cell)Tj
0 -1.2375 TD
(mass in chronic inflammation. J Clin Invest 1994;93:2379-86.)Tj
-2.175 -1.2375 Td
[(10.)-875.1 (Roubenof)17.7 (f R, Heymsfield S, Kehayias J, Cannon J, Rosenber)17.7 (g I.)]TJ
2.175 -1.2375 Td
(Standardization of nomenclature of body composition in weight)Tj
T*
[(loss. )54.8 (Am J Clin Nutr 1997;66:192-6.)]TJ
-2.1381 -1.2375 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Rall L, Rosen C, Dolnikowski G, et al. Protein metabolism in)]TJ
2.1381 -1.2375 Td
[(rheumatoid arthritis and aging: Ef)17.7 (fects of muscle strength training)]TJ
T*
[(and tumor necrosis factor)19.7 (-alpha. )54.8 (Arthritis Rheum 1996;39:1)36.8 (1)36.8 (15-24.)]TJ
-2.175 -1.2375 Td
[(12.)-875.1 (T)35 (isdale MJ. Loss of skeletal muscle in cancer: biochemical )]TJ
2.175 -1.2375 Td
(mechanisms. Front Biosci 2001;6:D164-74.)Tj
-2.175 -1.2375 Td
[(13.)-875.1 (Moldawer LL, Rogy MA, Lowry SF)79.7 (. )17.7 (The role of cytokines in)]TJ
2.175 -1.2375 Td
(cancer cachexia. J Parenter Enteral Nutr 1992;16:43S-9S.)Tj
-2.175 -1.2375 Td
[(14.)-875.1 (Chang HR, Dulloo )54.8 (AG, Bistrian BR. Role of cytokines in )54.8 (AIDS)]TJ
2.175 -1.2375 Td
[(wasting. Nutrition 1998;14\(1)36.8 (1/12\):853-63.)]TJ
-2.175 -1.2375 Td
[(15.)-875.1 (Grunfeld C, Feingold KR. Metabolic disturbances and wasting in)]TJ
2.175 -1.2375 Td
(the acquired immunodeficiency syndrome. N Engl J Med)Tj
0 Tc 0 Tw T*
(1992;327:329-37.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2375 Td
[(16.)-875.1 (Costelli P)110.7 (,)-0.1 ( Carbo N, )17.7 (T)69.9 (essitore L, et al. )17.7 (T)35 (umor necrosis factor)19.7 (-alpha)]TJ
2.175 -1.2375 Td
(mediates changes in tissue protein turnover in a rat cancer cachexia)Tj
T*
(model. J Clin Invest 1993;92:2783-9.)Tj
-2.175 -1.2375 Td
[(17.)-875.1 (Llovera M, Lopez-Soriano FJ, )54.8 (Ar)17.7 (giles JM. Ef)17.7 (fects of tumor)]TJ
2.175 -1.2375 Td
[(necrosis factor)19.7 (-alpha on muscle-protein turnover in female )17.7 (W)39.8 (istar)]TJ
T*
(rats. J Natl Cancer Inst 1993;85:1334-9.)Tj
-2.175 -1.2375 Td
[(18.)-875.1 (Goodman MN. )17.7 (T)35 (umor necrosis factor induces skeletal muscle)]TJ
2.175 -1.2375 Td
[(protein breakdown in rats. )54.8 (Am J Physiol 1991;260:E727-30.)]TJ
-2.175 -1.2375 Td
[(19.)-875.1 (Starnes HFJ, )17.7 (W)79.9 (arren RS, Jeevanandam M, et al. )17.7 (T)35 (umor necrosis)]TJ
2.175 -1.2375 Td
(factor and the acute metabolic response to tissue injury in man. )Tj
T*
(J Clin Invest 1988;82:1321-5.)Tj
-2.175 -1.2375 Td
[(20.)-875.1 (Flores EA, Bistrian BR, Pomposelli JJ, et al. Infusion of tumor)]TJ
2.175 -1.2375 Td
[(necrosis factor/cachectin promotes muscle catabolism in the rat. )54.8 (A)]TJ
T*
[(syner)17.7 (gistic ef)17.7 (fect with interleukin 1. J Clin Invest 1989;83:1614-22.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Ling PR, Schwartz JH, Bistrian BR. Mechanism of host wasting)]TJ
2.175 -1.25 Td
[(induced by administration of cytokines in rats. )54.8 (Am J Physiol)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1997;272:E333-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Arnett F)79.7 (, Edworthy S, Bloch D, et al. )17.7 (The )54.8 (American Rheumatism)]TJ
2.175 -1.25 Td
(Association 1987 revised criteria for the classification of )Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
30.825 80.2709 Td
[(23.)-875.1 (Kehayias J, Fiatarone M, Zhuang H, Roubenof)17.7 (f R. )17.7 (T)69.9 (otal body)]TJ
2.175 -1.25 Td
[(potassium and body fat: relevance to aging. )54.8 (Am J Clin Nutr)]TJ
0 Tc 0 Tw T*
(1997;66:904-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Roubenof)17.7 (f R, )17.7 (W)79.9 (alsmith J, Lundgren N, Snydman L, Dolnikowski)]TJ
2.175 -1.25 Td
[(GJ, Roberts S. Low physical activity reduces total ener)17.7 (gy )]TJ
T*
(expenditure in women with rheumatoid arthritis: implications for)Tj
T*
[(dietary intake recommendations. )54.8 (Am J Clin Nutr 2002;76:774-9.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Rall L, Meydani S, Kehayias J, Dawson-Hughes B, Roubenof)17.7 (f R.)]TJ
2.175 -1.25 Td
[(The ef)17.7 (fect of progressive resistance training in rheumatoid arthritis:)]TJ
T*
[(increased strength without changes in ener)17.7 (gy balance or body)]TJ
T*
[(composition. )54.8 (Arthritis Rheum 1996;39:415-26.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Fries J. )17.7 (The dimensions of health outcomes: the Health )54.8 (Assessment)]TJ
2.175 -1.25 Td
(Questionnaire. J Rheumatol 1982;9:786-93.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Dallal G. PC-Size: Consultant \321 )54.8 (A)-220.1 (program for sample size )]TJ
2.175 -1.25 Td
[(determinations. )54.8 (Am Stat 1990;44:243.)]TJ
0 Tc -2.175 -1.25 Td
[(28.)-875 (Hochber)17.8 (g M, Chang R, Dwosh I, Lindsey S, Pincus )17.7 (T)74.1 (, )17.7 (W)80 (olfe F)79.8 (. )17.7 (The)]TJ
-0.00011 Tc 2.175 -1.25 Td
(American College of Rheumatology 1991 revised criteria for the)Tj
T*
(classification of global functional status in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:498-502.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Roubenof)17.7 (f R, Kehayias JJ. )17.7 (The meaning and measurement of lean)]TJ
0 Tc 2.175 -1.25 Td
(body mass. Nutr Rev 1991;46:163-75.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875.1 (V)59.8 (reugdenhil G, Lowenber)17.7 (g B, )17.7 (V)110.8 (an Eijk HG, Swaak )54.8 (AJ. )17.7 (T)35 (umor)]TJ
2.175 -1.25 Td
[(necrosis factor)19.7 (-alpha is associated with disease activity and the)]TJ
T*
(degree of anemia in patients with rheumatoid arthritis. Eur J Clin)Tj
T*
(Invest 1992;22:488-93.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Eastgate JA, )17.7 (W)79.9 (ood NC, DiGiovine FS, Symons JA, Grinlinton FM,)]TJ
2.175 -1.25 Td
[(Duf)17.7 (f GW)91.7 (. Correlation of plasma interleukin-1 levels with disease)]TJ
T*
(activity in rheumatoid arthritis. Lancet 1988;2:706-9.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Robak )17.7 (T)74 (, Gladalska )54.8 (A, Stepien H, Robak E. Serum levels of )]TJ
2.175 -1.25 Td
(interleukin-6 type cytokines and soluble interleukin-6 receptor in)Tj
T*
(patients with rheumatoid arthritis. Med Inflamm 1998;7:347-53.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Feldmann M, Brennan FM, Maini RN. Role of cytokines in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis. )54.8 (Annu Rev Immunol 1996;14:397-440.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Guttridge DC, Mayo MW)91.7 (, Madrid L)91.7 (V)128.9 (, )17.7 (W)79.9 (ang CY)128.8 (, Baldwin )54.8 (AS Jr)54.8 (.)]TJ
2.175 -1.25 Td
(NF-kB-induced loss of MyoD messenger RNA: possible role in)Tj
T*
(muscle decay and cachexia. Science 2000;289:2363-6.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Frost RA, Lang CH, Gelato MC. )17.7 (T)35 (ransient exposure of human)]TJ
2.175 -1.25 Td
[(myoblasts to tumor necrosis factor)19.7 (-alpha inhibits serum and )]TJ
T*
[(insulin-like growth factor)19.7 (-I stimulated protein synthesis.)]TJ
0 Tc T*
(Endocrinology 1997;138:4153-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(36.)-875.1 (Sakurai )36.8 (Y)128.9 (,)-0.1 ( Zhang XJ, )17.7 (W)79.9 (olfe RR. )17.7 (TNF directly stimulates glucose)]TJ
2.175 -1.25 Td
[(uptake and leucine oxidation and inhibits FF)73.9 (A)-220.1 (flux in conscious)]TJ
T*
[(dogs. )54.8 (Am J Physiol 1996;270:E864-72.)]TJ
-2.175 -1.25 Td
[(37.)-875.1 (Greiwe JS, Cheng B, Rubin DC, )36.8 (Y)99.8 (arasheski KE, Semenkovich CF)79.7 (.)]TJ
2.175 -1.25 Td
(Resistance exercise decreases skeletal muscle tumor necrosis factor)Tj
T*
[(in frail elderly humans. F)73.9 (ASEB J 2001;15:475-82.)]TJ
-2.175 -1.25 Td
[(38.)-875.1 (Li )36.8 (Y)110.8 (-)0.2 (P)110.7 (, Schwartz RJ, )17.7 (W)79.9 (addell ID, Holloway BR, Reid MB. Skeletal)]TJ
2.175 -1.25 Td
[(muscle myocytes under)17.7 (go protein loss and reactive )]TJ
T*
(oxygen-mediated NF-kB activation in response to tumor necrosis)Tj
T*
[(factor)19.7 (-a. F)73.9 (ASEB J 1998;12:871-80.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Stouthard JM, Goey H, de )17.7 (V)59.8 (ries EG, et al. Recombinant human)]TJ
2.175 -1.25 Td
(interleukin 6 in metastatic renal cancer: a phase II trial. Br J Cancer)Tj
0 Tc 0 Tw T*
(1996;73:789-93.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (Oldenbur)17.7 (g HS, Rogy MA, Lazarus DD, et al. Cachexia and the)]TJ
2.175 -1.25 Td
(acute-phase protein response in inflammation are regulated by)Tj
T*
(interleukin-6. Eur J Immunol 1993;23:1889-94.)Tj
-2.175 -1.25 Td
[(41.)-875.1 (Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the)]TJ
2.175 -1.25 Td
(involvement of interleukin 6 in experimental cancer cachexia. )Tj
T*
(J Clin Invest 1992;89:1681-4.)Tj
-2.175 -1.25 Td
[(42.)-875.1 (Roubenof)17.7 (f R, Roubenof)17.7 (f R, )17.7 (W)79.9 (ard L, Stevens M. Catabolic ef)17.7 (fects)]TJ
2.175 -1.25 Td
(of high-dose corticosteroids persist despite therapeutic benefit in)Tj
T*
[(rheumatoid arthritis. )54.8 (Am J Clin Nutr 1990;52:1)36.8 (1)36.8 (13-7.)]TJ
/T1_2 1 Tf
-35.4875 -8.5549 Td
[(W)91.9 (alsmith, et al: TNF-)]TJ
/T1_3 1 Tf
0 Tc 0 Tw 8 0 1.7005 8 124.5727 36.0898 Tm
(\002)Tj
/T1_2 1 Tf
-0.00011 Tc 8 0 0 8 131.8196 36.0898 Tm
[(pr)36.8 (oduction)]TJ
0 Tc 52.2726 -0.0444 Td
(29)Tj
ET
0 0 0 1 K
55 54 m
559 54 l
S
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\7!H*QE%*SZ8R."jD`car]V4^PHY0u_t8CPLs*9R6'TCoCRko(FUTALa)?2]/;
k53Esf62#GgA]?/2f-4:)k6fBf=iUBCqn^n$N1tV>#Mm&G/nt0`Wldg>*ud/\_M]T
'->=I[\>_^msR]g0'ccnj,@/NcnO:(=qmXFSe%A8XFZNm2[:[S1cBS\nbH>l5cU&B
@5^F;^;WiB,[JebjK5e$J/SoUQ>G2halcR*iaUBa(YnCHJrF>4f*Y$EsN/R!$J">\'^T$9WIgb,NL89N3k'_ZN'QlT+&dYD,GnX6Q8XlJ?eta
kGus9^d3"jNjSGD%sr\m0dF+F-o%)H8-RW#dp7c#h2R6E_&B])![-FHYgsXXb)KtX
,I+nn3gqC0o%?cSNN.gddX>2RK7)QVK
Hu-F0,&RHdF,/)O,F@-tjqB*moM;D6I*<$'"!/\#Z:F:`%?&+(;r\R%htTiLAUR))S6EkOg$"YqC>P2
CingWQD0/,e8bXL,!D_Wp'>C91M!-4A(2ft:3BMd.r-4K*1KrP#<6B`fX:FAPB7oR
ON'F0JjBVZHYF^?g[7]N/-aD1UlBXRN&Ms/i>B2Nij4;F,/&;C,Q?DV!fe1$&V%q)
A(T)sqdUN$/tt@b:*Rn2^Bt$S)#V@h
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
39 0 obj
<>
endobj
89 0 obj
<>
endobj
83 0 obj
<>
endobj
79 0 obj
<>
endobj
118 0 obj
<>
endobj
138 0 obj
<>
endobj
82 0 obj
<>
endobj
80 0 obj
<>
endobj
78 0 obj
<>stream
HT=o0w~ǫ:PC?TH q'u汝8oX\`Έg:4$)H%c:7ۼ@UE'mpj7ػ|xЮpB@!bkgߺ }h
<9.4g t8>P;a!i=HI='C5'p&}[jOCpƅex!@AA